Procyon BioPharma Inc. To Present PCK3145 Mechanism At The Angiogenesis Foundation's 3rd Annual Symposium
Published: Oct 20, 2005
MONTREAL, Oct. 20 /PRNewswire-FirstCall/ - Procyon Biopharma Inc. announced today that on Friday, October 21, Dr. Chandra Panchal, senior executive vice-president, new technologies, will present the mechanism of action of PCK3145 at the Angiogenesis Foundation's 3rd Annual Symposium held in Boston.
The Angiogenesis Foundation's 3rd Annual Symposium on Antiangiogenesis: New Frontiers in Therapeutic Development, features key note addresses by world leaders in endothelial biology: Dr. Louis Ignarro, 1998, Nobel Laureate, and Dr. Judah Folkman of Harvard Medical School, pioneer of the field of angiogenesis research.
"We are honored to be part of a highly reputable faculty including speakers from the academic and the international pharmaceutical industry," said Hans J. Mader, president and chief executive officer of Procyon Biopharma.
Procyon's presentation titled: "PCK3145: A Novel signal transduction inhibitor for treating late stage prostate cancer," will take place at 1:00 P.M. ET. Dr. Panchal will discuss the experimental evidence supporting the "multitasking" effect (pro-apoptotic, anti-angiogenic and signal transduction inhibition) of PCK3145, Procyon's drug candidate for treatment of advanced metastatic prostate cancer.
ABOUT PCK3145 THERAPEUTIC PEPTIDE
PCK3145 is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the prostate is down regulated in patients with advanced prostate cancer, and believed to be a survival mechanism for the cancer cells. Results from the Phase IIa trial of PCK3145 confirmed PCK3145 to be safe and well tolerated at all doses tested further suggest that it also plays a role in preventing the metastatic process as measured by its effect on Matrix Metalloproteinase-9 (MMP-9) levels, a Gelatinase B enzyme involved in angiogenesis, tumor invasion and metastasis. Procyon has filed an investigational new drug (IND) application with the FDA. A pilot study as a lead-in to a North American Phase II study is underway. The mechanism of action and receptor for PCK3145 suggests PCK3145 to be a signal transduction inhibitor with multiple ways (apoptosis, anti-angiogenesis and anti-metastasis) to restrict disease development.
ABOUT PROCYON BIOPHARMA INC.
Procyon Biopharma Inc. is a biotechnology company actively engaged in the discovery and development of innovative therapeutics in the fields of cancer and HIV/AIDS. The Company leverages its strengths in research and clinical development, bringing products through late-stage clinical trials and then evaluating the best options for further development, such as co-development and licensing. Procyon's pipeline includes: PCK3145, a non-toxic peptide soon to enter a Phase II North American trial for the treatment of advanced prostate cancer; TVT-Dox, a tumor vasculature targeting technology for the treatment of solid tumors for which an IND filing is expected within 12 months; and, PPL-100, a protease inhibitor for the treatment of drug-resistant HIV/AIDS soon to enter the clinic. Procyon has won the 2005 Frost & Sullivan Award for Excellence in Technology for its overall scientific and technological contributions towards the advancement of cancer therapy. Headquartered in Montreal, Procyon shares are listed on the Toronto Stock Exchange (TSX) under the ticker symbol PBP. For more information, visit www.procyonbiopharma.com .
This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's filings.PROCYON BIOPHARMA INC.
CONTACT: Procyon Biopharma Inc.: Julie M. Thibodeau,email@example.com , firstname.lastname@example.org , (514) 685-2000,ext 118 ; The Trout Group: Christine Labaree - email@example.com ,(781) 685-2934; Marcy Strickler - firstname.lastname@example.org , (212)477-9007, ext. 27; Echoes Financial Network Inc.: Dominic Sicotte -email@example.com ; Martin Lavoie - firstname.lastname@example.org , (866)633-9551